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The Antibody-Secreting Cell 
Response to infection: Kinetics and 
Clinical Applications
Michael J. Carter 1*, Ruth M. Mitchell1, Patrick M. Meyer Sauteur 2, Dominic F. Kelly 1 and 
Johannes Trück1,2
1 Oxford Vaccine Group, Department of Paediatrics, University of Oxford, NIHR Oxford Biomedical Research Centre, Oxford, 
United Kingdom, 2 University Children’s Hospital, Zurich, Switzerland
Despite the availability of advances in molecular diagnostic testing for infectious dis-
ease, there is still a need for tools that advance clinical care and public health. Current 
methods focus on pathogen detection with unprecedented precision, but often lack 
specificity. In contrast, the host immune response is highly specific for the infecting 
pathogen. Serological studies are rarely helpful in clinical settings, as they require acute 
and convalescent antibody testing. However, the B cell response is much more rapid 
and short-lived, making it an optimal target for determining disease aetiology in patients 
with infections. The performance of tests that aim to detect circulating antigen-specific 
antibody-secreting cells (ASCs) has previously been unclear. Test performance is reliant 
on detecting the presence of ASCs in the peripheral blood. As such, the kinetics of 
the ASC response to infection, the antigen specificity of the ASC response, and the 
methods of ASC detection are all critical. In this review, we summarize previous stud-
ies that have used techniques to enumerate ASCs during infection. We describe the 
emergence, peak, and waning of these cells in peripheral blood during infection with 
a number of bacterial and viral pathogens, as well as malaria infection. We find that 
the timing of antigen-specific ASC appearance and disappearance is highly conserved 
across pathogens, with a peak response between day 7 and day 8 of illness and largely 
absent following day 14 since onset of symptoms. Data show a sensitivity of ~90% 
and specificity >80% for pathogen detection using ASC-based methods. Overall, the 
summarised work indicates that ASC-based methods may be very sensitive and highly 
specific for determining the etiology of infection and have some advantages over cur-
rent methods. Important areas of research remain, including more accurate definition 
of the timing of the ASC response to infection, the biological mechanisms underlying 
variability in its magnitude and the evolution and the B  cell receptor in response to 
immune challenge. Nonetheless, there is potential of the ASC response to infection to 
be exploited as the basis for novel diagnostic tests to inform clinical care and public 
health priorities.
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FiguRe 1 | Differentiation of B cells in response to antigen. B cells receive activating signals by at least two pathogen non-specific mechanisms, pattern-
recognition receptors (PRRs), and the cytokine context of the immune response; and two antigen-specific mechanisms, interactions with cognate T cells via the 
T cell receptor (TCR) and other ligands and B cell receptors (BCR)–antigen interaction. Integration of these signals predisposes the fate of the maturing B cell to a 
certain phenotype for the lifespan of the cell, simplistically resulting in plasmablasts, long-lived plasma cells (LLPCs), and memory B cells.
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iNTRODuCTiON
The production of pathogen-specific antibody by B lymphocytes 
(B cells) is of key importance for protection from infection. Naive 
B  cells are activated through interaction with foreign antigen, 
cognate T cell receptors (TCRs) (1), pattern-recognition recep-
tors (2), and cytokines (3) to form antigen-specific antibody-
secreting cells (ASCs; plasmablasts and plasma cells), memory 
B cells and other subsets (4, 5) (Figure 1). Increasing insights into 
the cellular aspects of humoral immunity are emerging through 
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a focus on plasmablasts. These are ASCs produced following 
antigen challenge that transiently circulate through peripheral 
blood before migrating to secondary lymphoid organs or bone 
marrow, or undergoing apoptosis. Plasmablasts thus represent an 
accessible and measurable subset of ASCs only detectable during 
an acute immune response.
Measurements of plasmablasts have been used extensively to 
describe the humoral immune response following vaccination 
(6). Measurements of plasmablasts may also provide data to 
inform the humoral response to infection and may translate into 
novel diagnostic tests. The development of novel diagnostic tests 
based on the plasmablast response to infection may circumvent 
difficulties with culture of organisms (usually lack of sensitivity 
due to difficulty accessing tissue and prior antibiotic adminis-
tration), serological testing (usually lack of specificity unless a 
convalescent sample is also taken), or PCR-based methods (often 
lack of specificity, excepting testing of CSF). Additionally, the 
B  cell receptors (BCRs) of plasmablasts are membrane-bound 
antibodies. As such, these BCRs could be used to inform vaccine 
development or to develop therapeutic monoclonal antibodies 
(7). Such therapeutic antibodies may be particularly important 
in the context of emerging infections or increasing antimicrobial 
resistance.
Antibody specificity and isotype and timing of the plasma-
blast response to infection are key to accurate measurements. 
However, these data have not previously been systematically 
reviewed. In this review we describe the data that exist on the 
timing and magnitude (kinetics) of the antigen-specific B  cell 
responses following infection in humans. Our focus on ASCs (or 
where possible, the more specific subset of plasmablasts) reflects 
their importance in the production of antibodies, their dynamic 
numbers, and their transience in the peripheral blood: aspects 
of fundamental importance to their clinical applications. Where 
generated, memory B cells tend to persist at a low frequency; as 
so, they are not our focus, but have been recently reviewed in 
detail (8).
Search strategy. We searched MEDLINE with combinations 
of the following terms “B cell,” “plasmablast,” “plasma cell,” “anti-
body-secreting cell” AND “infection” AND “kinetics,” “dynamics.” 
We identified peer-reviewed articles of interest, and conducted 
further searches for terms identified as important (e.g. “antibodies 
lymphocyte supernatant,” “ELISpot,” “B cell receptor sequencing” 
in the context of infection).
TeCHNiQueS FOR MeASuRiNg 
ANTigeN-SPeCiFiC B CeLL ReSPONSeS
Challenges of Measuring B Cell 
Responses to infection in Humans
Comparison of the ASC response to natural infection across stud-
ies is limited by varying definitions of ASC subsets. Here we use 
the term ASC to include all ASCs as defined by ex vivo assays such 
as enzyme-linked immunospot assay (ELISpot; below). We use 
the term plasmablast for ASCs that depict recognized cell surface 
markers for this B cell subset following immunophenotyping (9). 
We have eschewed the term “plasma cells” for clarity, since we 
will not discuss (usually sessile) long-lived plasma cells further. In 
general, numbers of ASCs are described as number per unit of 
blood, as a proportion of peripheral blood mononuclear cells 
(PBMCs), or as a proportion of peripheral blood B cells, as dictated 
by the techniques available to research teams (10). Antigen-specific 
ASCs may be further defined as a proportion of total (isotype-
specific) ASCs (7), with varying definitions of antigen specificity.
Techniques for Counting Specific  
Subsets of Cells
Fluorescence-based (flow) cytometry distinguishes immu-
nophenotypes of cells by the binding of fluorescing monoclonal 
antibodies to defined cell surface markers. Thus, flow cytometry 
allows investigators to sort plasmablasts from other PBMCs. 
Markers of recent proliferation may be used to enrich samples 
for acutely proliferated plasmablasts, which may enhance 
specificity for the etiological diagnosis of acute infection (11). 
Replicability of experiments over time and between laboratories 
is paramount. As such, optimized panels of reagents for identi-
fying specific populations and automated gating strategies have 
been developed (12).
ELISpot identifies subsets of cells by the binding of antibody to 
a chosen membrane-bound antigen. The addition of a substrate 
causes a color change where bound antibody is present, with the 
appearance of a spot corresponding to a single antigen-specific 
ASC (13). ELISpot is thus a highly sensitive technique because 
individual cells can be easily identified and counted. ELISpot 
is adaptable and can be applied to populations of cells that are 
either sorted by flow cytometry, or PBMCs separated from whole 
blood using density-dependent centrifugation. Although here 
we describe the detection of antigen-specific ASCs by the use of 
ELISpot and assay of antibody from lymphocyte supernatant (ALS) 
(Table 1), ELISpot has also been used for the immunophenotyp-
ing of B cell subsets for a variety of non-immunoglobulin markers 
(14). Unlike flow cytometry, ELISpot is a robust technique and 
can be used in laboratories in a variety of settings (10). A constitu-
tive limitation to ELISpot, is the need for either PBMCs that have 
been recently sampled, or PBMCs that have been cryopreserved 
(15). Since antigen-specific ASCs form only a small proportion 
of PBMCs, even during the peak of an immune response, the 
number of antigen-specific ASCs limits the number of antigens 
that can be assayed. In addition, if fresh PBMCs are used, ELISpot 
plates must be prepared with predetermined antigens.
Other Techniques to Assess Antigen-
Specific ASCs
Assay of ALS measures the sum of antibodies produced by ASCs 
during a period of in  vitro cell culture. The method is simple: 
peripheral blood is sampled, and PBMCs are separated by density-
dependent centrifugation, washed, and incubated for 24–48 h in 
cell culture media (44). The resulting supernatant is enriched for 
antibodies that were secreted during ex vivo incubation by recently 
activated ASCs. As with ELISpot, this technique has potential to be 
developed into a diagnostic test for the etiology of acute infections 
and has already been applied with some success to clinical tuber-
culosis (26, 27, 45) and enteric fever (22, 23), as well as vaccine 
TABLe 1 | Studies investigating the use of eLiSpot and ALS for the diagnosis of infection.
Disease/
pathogen
Setting Methods and study patients/volunteers Results Reference
Enterotoxigenic 
Escherichia coli 
dysentery
USA  
(challenge 
study)
20 adult volunteers with live oral attenuated ETEC vaccine; 20 adult volunteers  
with ETEC oral challenge
ALS against E. coli antigens IgA: positive in 75–95% of infected subjects. 
ELISpot: positive in 85–100% of infected subjects (depending on antigen 
measured)
Carpenter  
et al. (16)
Comparison of ELISpot assays for IgA ASCs and IgA ALS (for IgA) at  
day 0, day 7, and day 21 following challenge
ALS against CFAII IgA: positive in 75% of vaccinees; ELISpot: positive  
in 90% of infected subjects
Antigens for ALS ELISA, time-resolved fluorescence antibody assay,  
and ELISpot: CFA/II (vaccinees); LT, CS3, CS1 (infected subjects)
Both ALS and ELISpot considerably higher than fecal IgA measurements  
against matched antigens
Urban  
Bangladesh
46 adult and child patients with CS6-expressing ETEC diarrhea, 10 local  
adult \controls, and 10 local child controls
ALS against CS6: 89% with positive with IgA, 100% positive with IgG.  
ELISpot against CS6: 100% positive with IgA (GMC 430 ASC/million  
PBMC), 75% positive with IgG.
Qadri  
et al. (17)
Comparison of ELISpot assays for ASCs on 12 adult patients and ALS  
for all 46 patients, at day 2 and day 7, versus ELISpot and ALS on healthy  
controls. Antigens for ALS and ELISpot: CS6 and CS5 + CS6
No responses detectable by ALS or ELISpot in healthy controls
Shigella spp. 
dysentery
USA  
(challenge 
study)
30 adult volunteers with oral live attenuated S. dysenteriae type 1a vaccine;  
10 adult volunteers with S. flexneri 2a oral challenge
ALS for Shigella-LPS IgA ASCs: sensitivity of 79%, specificity of 75% versus 
ELISpot. ALS for Shigella-LPS IgA ASCs: sensitivity of 79%, specificity of 75% 
versus ELISpot. Details on timing or magnitude of ASC responses by ELISpot  
of ALS not given.
Feller  
et al. (18)
Comparison of ELISpot assays for ASCs and ALS (for IgA and IgG). No  
details of time points
Antigens for ELISA of ALS and ELISpot: Shigella-LPS
Cholera Urban  
Bangladesh
30 adult patients with acute cholera and 10 local healthy controls Peak cholera-specific ASCs at day 7 (median peak CtxB-specific IgA  
ASCs ~ 350/million PBMCs, LPS-specific IgA ASCs ~900/million PBMCs)
Qadri  
et al. (19)
Comparison of ELISpot assays for IgA ASCs and IgA ALS at presentation to  
hospital and day 7. Antigens for ALS and ELISpot: CTxB, cholera LPS and MSHA
ALS for IgA CtxB-specific ASCs: sensitivity of 94% versus vibriocidal serum 
response. ELISpot for IgA LPS-specific ASCs: sensitivity of 94% versus  
vibriocidal serum response 
Urban  
Bangladesh
17 children 3–5 years of age, 17 older children and 68 adults with acute cholera. Similar antibody/ASC responses across age groups. Returned to baseline by day 30 Leung  
et al. (20)Comparison of vibrocidal antibodies, antigen-specific antibodies, ELISpot for  
IgM/A/G ASCs and (stimulated) memory B cells at day 2, day 7, and day 30
Peak cholera-specific ASCs at day 7 (median peak CtxB-specific IgA ASCs 
~100–200/million PBMCs, LPS-specific IgA ASCs ~200–400/million PBMCs)
Urban  
Bangladesh
Nine adult patients with acute cholera infection, eight adults vaccinated with  
oral cholera vaccine (Dukoral)
Median peak CtxB-specific IgG ASCs at ~370/million PBMCs (patients) and 
~200/million PBMCs (vaccinees)
Rahman  
et al. (21)
Comparison of ASC responses between infection and post-vaccination using  
ELISpot (antigens: CtxB and cholera LPS) on days 2, 7, and 30 (infection) and  
days 0, 7, and 21 (vaccination)
Detectable CtxB/LPS-specific IgA/IgG ASC responses in 9/9 patients and  
5/8 post-vaccination at day 7 (returned to baseline during convalescence)
Enteric fever Urban  
Bangladesh
112 adult and child patients with fever of unknown etiology of 3–7 days  
duration
IgA ALS against LPS and whole-cell preparation: sensitivity 88% versus  
blood culture
Sheikh  
et al. (22)
Comparison of ALS and plasma antibodies versus comparator standards  
(classic clinical presentation, Widal titer, blood culture) at day 0, day 5, and  
day 20 following presentation
IgA ALS and plasma antibodies across comparator groups supports  
possibility of ALS detecting blood culture-negative enteric fever
Antigens for IgA and IgA ALS: typhoid LPS, whole-cell preparation, and 
membrane preparation (MP)
Rural  
Bangladesh
243 adult and child patients with clinically suspected enteric fever (39 blood 
culture positive), 32 febrile (non-enteric fever) controls (both groups with fever of 
3–7 days duration), and 74 local healthy controls
Sensitivity of 100% for blood culture positive enteric fever, specificity  
of 78–97% (depending on definition of a true-negative case)
Khanam  
et al. (23)
ALS at presentation to hospital/enrollment (all patients/controls) and day 7 and  
day 21 in 38 patients. Antigens for IgA ALS: typhoid MP
(Continued)
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Disease/
pathogen
Setting Methods and study patients/volunteers Results Reference
Tuberculosis Urban  
Bangladesh
49 adult patients with smear-positive pulmonary TB; 35 adult patients with  
other pulmonary diseases; 35 healthy local controls
IgG ALS against BCG: sensitivity of 93% and specificity of 80% to  
detect smear-positive in pulmonary TB
Raqib  
et al. (24)
ALS at presentation to hospital only. Antigens for IgG ALS: BCG and PPD  
Urban  
Bangladesh
58 child patients with clinical TB; 16 child patients with other infections; 58  
healthy child controls
Of patients with clinical TB: 15% positive by culture of sputum/gastric lavage, 
64% positive by published clinical scoring charts, 91% positive by ALS
Raqib  
et al. (25)
ALS for all patients/controls (and standard microbiology for patients) at day 1,  
day 60, and day 180 following presentation. Antigens for ALS: BCG
All children with TB had significantly higher ALS titers that non-TB patients  
or controls. Declining ALS titers in children with active disease following  
treatment
Urban  
Bangladesh
212 adult patients with suspected TB; 100 adult patients with other diseases;  
25 healthy adult controls
Sensitivity of 91%, specificity of 88% specificity using BCG-specific  
IgG ALS for pulmonary TB (smear/culture positive) versus non-TB patients
Rekha  
et al. (26)
ALS at presentation to hospital only. Antigens for ALS: BCG and other  
M. tuberculosis antigens
Urban Ethiopia 84 adult patients with smear-negative symptomatic TB (pulmonary, pleural,  
and lymph node); 12 adult patients with other diseases; 45 adult patients  
with latent TB; 40  
non-TB controls 
BCG-specific plasmablasts median of 6% of plasmablasts in symptomatic  
TB versus 3% in latent TB (p < 0.001)
Ashenafi  
et al. (27)
Comparison of IgG ALS, BCG-specific plasmablast enumeration (flow cytometry), 
Quantiferon Gold, tuberculin skin test. Antigens for IgG ALS: BCG
ALS: 86–90% sensitivity, 80% specificity for symptomatic TB versus latent  
TB. ALS: 86–91% sensitivity, 94% specificity for symptomatic TB versus  
non-TB controls
Urban  
Bangladesh
224 patients <5 years of age with severe malnutrition and radiological features  
of pneumonia/pulmonary infection. 15 patients with microbiologically confirmed  
TB; 41 patients with non-confirmed TB; 168 patients not TB
Similar proportions of “positive,” “bordeline” and “negative” ALS results  
between three groups (confirmed TB, non-confirmed TB, not TB)
Chisti  
et al. (28)
ALS at presentation to hospital. Antigens for IgG ALS: BCG Sensitivity of 67% and specificity of 51% for confirmed TB versus not TB.
Urban China 62 adult patients with culture-positive pulmonary TB; 53 adult patients with  
other pulmonary diseases; 47 healthy adult controls
ALS: 97% sensitivity, 85% specificity for culture-positive TB versus healthy 
controls. ALS: 68% sensitivity and 93% specificity for culture-positive  
TB versus patients with other pulmonary diseases
Jiao  
et al. (29)
IgG ALS at presentation to hospital only. Antigens for IgG ALS: M. tuberculosis  
acid phosphatase
Pneumococcus 
and other  
bacterial 
respiratory 
pathogens
Finland 16 adult patients with bacteremic pneumococcal pneumonia and 14 healthy  
controls
All patients had pneumococcal-specific IgG ASCs ≥10/million PBMCs  
(range 10–1,000/million); all controls had 0–1/million PBMCs detected:  
sensitivity and specificity of 100% in this small retrospective case series
Palkola et al. (30)
ELISpot to detect pneumococcal-specific IgM/A/G ASCs on day 7 following  
bacteremia or from healthy controls. Antigens for ELISpot: patient’s pathogen,  
or mixed capsular polysaccharides (controls)
Finland 24 adult patients with acute sinusitis of acute tonsillitis and 9 adult healthy  
controls
All patients had pathogen-specific IgG ASCs ≥10/million PBMCs  
(range 10–1,000/million PBMCs); controls had no pathogen-specific ASCs  
detected: sensitivity and specificity of 100% in this case series
Palkola  
et al. (31)
Streptococcus pneumoniae, H. influenza, and β-hemolytic streptococci isolated  
from patient swabs
Patient blood samples taken 7–14 days following onset of symptoms
ELISpot to detect antigen-specific IgM/A/G ASCs patient’s pathogen and  
pathogen  
panel for controls
TABLe 1 | Continued
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Disease/
pathogen
Setting Methods and study patients/volunteers Results Reference
UTI caused by 
E. coli and other 
bacteria
Finland 10 adult patients with lower UTI and 17 patients with pyelonephritis due to  
E. coli, Enterococcus spp., Enterobacter spp., and staphylococci
Pathogen-specific IgA ASCs in 100% of patients with pyelonephritis  
(mean 787, 95% CI 738–836/million PBMCs) and 70% of patients with  
lower UTI (mean 6 95% CI 6–12/million PBMCs). Lower responses for  
other Ig isotypes
Kantele et al. (32)
Patient blood samples 7 days following onset of symptoms and in  
convalescence
ELISpot to detect antigen-specific IgM/A/G ASCs to patient’s own pathogen Downward trend in ASCs at convalescence, but pathogen-specific ASCs  
still detectable at 7 weeks in some patients
Finland 14 adult patients with lower UTI and 11 patients with pyelonephritis due to  
E. coli. [Patients previously report in Kantele et al. (32)]
IgA ASC responses greater than IgG and IgM; and responses to whole cell 
greater than to P fimbria and OmpA. Mean P fimbria-specific IgA ASC 294/ 
million PBMCs
Kantele et al. (33)
Patient blood samples at 7 days following onset of symptoms P fimbria-specific IgA ASC responses in 100% of patients with P fimbria- 
positive E. coli pyelonephritis, and 20% of those with P fimbria lower UTIELISpot to detect whole cell, P fimbria or OmpA-specific IgM/A/G ASCs
Finland 37 children with pyelonephritis due to E. coli Mean IgM ASC 19 cells, IgA ASC 16 cells, IgG 6 cells/million PBMCs. IgM 
predominating in children <2 years of age
Kantele et al. (34)
Patient blood samples 1–3 days following admission and 7 days following  
admission, and convalescence
33/37 (89%) children with detectable pathogen-specific ASCs. Responses 
correlated with increasing age, with four non-responders <1 year of age
ELISpot to detect IgM/A/G ASC to patient’s own pathogen and P fimbria
Influenza UK (challenge 
study)
12 healthy adult volunteers Median Br59-specific IgG ASCs 166 (IQR 111–121)/million PBMCs at day 7. 
Antigen-specific ASCs were absent at other time points. Antigen-specific  
ASCs correlated with viral load and symptom score
Huang et al. (35)
Blood samples at day −2, day 3, day 7, and day 28 relative to challenge
ELISpot to hemagglutinin to detect H1N1Br59-specific IgG ASCs
RSV UK (challenge 
study)
61 healthy adult volunteers Infected volunteers showed median peak RSV-specific IgG ASCs of ~ 
300/million PBMCs at day 10. Antigen-specific ASCs were undetectable prior to 
day 7 and after day 14. RSV-specific IgG ASCs were largely undetectable  
in on-infected volunteers
Habibi  
et al. (36)Blood samples at day 0, day 3, day 7, day 10, day 14, and day 28 relative  
to challenge
ELISpot to detect RSV-lysate-specific IgM/A/G ASCs 
USA 40 adult patients with RSV infection RSV-specific IgG ASCs detectable by day 2 of illness and detected in 90%  
of cases by day 11 (mean 200 RSV-specific IgG ASCs/million PBMCs).  
RSV-specific ASC responses were detectable in 48% of cases in  
convalescence (days 22–45)
Lee  
et al. (37)Blood samples at enrollment, days 10–16 and days 22–45 following onset  
of symptoms
ELISpot to detect RSV-F protein-specific IgG ASCs
USA 97 adult patients with respiratory virus infection in total; data presented on  
11 patients with RSV and 11 patients with influenza infection; and healthy  
controls including 19 adults recently vaccinated with against influenza, tetanus, 
HPV or HBV
RSV-specific IgG ASCs detectable by day 2 of illness, and detected in  
100% of cases by day 11 (median ~1,000 ASCs/million PBMCs) and absent  
in influenza infection and controls. Similarly, influenza-specific IgG ASCs  
detected in 100% of cases by days 4–11 (median peak ~1,000 ASCs/million 
PBMCs) and absent in RSV infection and controls
Lee  
et al. (38)
Patient blood samples at days 4–11 following symptom onset (enrollment),  
post-vaccine samples 6–7 days following vaccination
ELISpot to detect RSV-F protein-specific IgG ASCs, influenza antigens and  
vaccine antigens (as above)
TABLe 1 | Continued
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Dengue Urban  
Thailand
46 adult patients with severe dengue infection Median peak dengue-specific IgG ASCs ~15,000/million PBMCs (range 
10–150,000/million PBMCs). Lower responses with IgA and IgM ASCs.  
Dengue-virus specific ASCs absent from controls and in convalescence
Wrammert  
et al. (39)Patient blood samples on day of admission (median 6, range 2–8, days  
following onset of fever) and convalescence
ELISpot to detect dengue-virus-specific IgM/A/G ASCs (using purified  
dengue virions)
Brazil 84 child and adult patients with primary or secondary dengue infection,  
15 controls with fever from other causes, and 10 local healthy controls
Median peak dengue-specific IgG ASCs ~20,000/million PBMCs  
(range 3,000–100,000/million PBMCs), encompassing ~50% of all IgG  
ASCs (to any antigen)
Garcia-Bates  
et al. (40)
Patient blood samples on day of admission (median 6, range 1–9, days  
following  
onset of fever) and convalescence
Peak of IgG ASCs (to any antigen) between day 3.5 and day 7 following  
onset of symptoms and correlated with onset of symptoms
ELISpot to detect dengue-virus-specific IgG ASCs (using purified  
dengue virions)
 
Mumps USA  
 (outbreak)
Seven adult with acute mumps infection; 16 adult volunteers vaccinated with  
mumps virus vaccine (following previous infection/vaccination)
Mumps virus-specific ASCs 10–100/million PBMCs from day 7 to day 14  
(6 patients), and 1.5/million PBMCs on day 28 (1 patient)
Latner  
et al. (41)
Patient blood samples between day 7 and day 28 of onset of symptoms.  
Volunteer blood samples at day 0, day 7, and day 28 and 35 weeks
Pre-vaccine and 35 weeks post-vaccine samples all mumps virus-specific  
ASCs <0.5/million PBMCs
ELISpot to detect IgG ASCs to purified mumps virions 100% sensitivity and specificity for diagnosis of acute mumps infection
EV-71 Taiwan 28 children with acute EV-71 infection admitted to hospital Mean EV-71-specific IgM ASCs 472, IgA ASCs 187, IgG ASCs 491/million 
PBMCs
Huang  
et al. (42)
Blood samples on admission (mean 4.7 days following onset of symptoms)  
and convalescence
Responses largely undetectable from day 8 following onset of symptoms
ELISpot to detect IgM/A/G ASCs to purified EV-71 virions IgM ASC response predominated in younger children
Falciparum  
malaria
UK (challenge 
study)
Nine adult volunteers initially vaccinated with experimental merozoite  
(blood-stage) vaccine, subsequently exposed to malaria challenge infection
No detectable MSP1-specific IgG ASC responses at days 7, 11, and 35  
in volunteers undergoing malaria challenge infection (despite merozoite 
parasitemia by day 7)
Elias  
et al. (43) 
Blood samples at day –1, day 7, day 11, and day 35 following malaria  
challenge infection
Possible questions regarding lack of later time points (since merozoite 
parasitemia, not prehepatic sporozoites, may act as immune stimulus)
ELISpot to detect MSP1-specific IgG ASCs
ALS, antibody from lymphocyte supernatant; ASCs, antibody-secreting cells; CtxB, cholera toxin B subunit; PBMCs, peripheral blood mononuclear cells; LPS, lipopolysaccharide; MSHA, mannose-sensitive hemagglutinin; TB, 
tuberculosis; BCG, Bacille Calmette-Guérin; PPD, purified protein derivative; GMC, geometric concentration; ETEC, Enterotoxigenic Escherichia coli; CFA/II, E. coli colonizing factor; CS1, CS3, CS6, coli surface antigens; LT, heat-labile 
E. coli toxin; UTI, urinary tract infection; OmpA, outer membrane protein A; RSV, respiratory syncytial virus; HPV, human papillomavirus; HBV, hepatitis B virus; EV-71, Enterovirus-71; MSP1, merozoite surface protein 1; MP, membrane 
preparation.
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responses (16) (Table 1). Although frozen cells can also be used 
for the ELISpot (15), ALS samples can be more easily frozen and 
transported to centralized laboratories, allowing responses from 
many antigens from multiple pathogens to be assayed. This may 
be of importance given progress in serological techniques (46) 
and the re-emphasized need for seroepidemiology in the context 
of emerging infectious diseases (47). Important questions regard-
ing optimal timing of samples relative to onset of symptomatic 
infection and its sensitivity in comparison to ELISpot, remain.
At present, the use of ALS and ELISpot to detect antigen-
specific ASCs for the diagnosis of infection is largely limited to 
research laboratories, with the exception of an established T cell 
ELISpot test for tuberculosis [T-spot.TB (48)]. This reflects the 
need for rigorous standardization of laboratory procedures to 
detect antigen-specific ASCs (or their secretions) prior to clinical 
trials or implementation into clinical practice. ALS and ELISpot 
also require techniques that, although simple, will be unfamiliar 
to the majority of microbiology technicians such as the separa-
tion and washing of PBMCs from fresh blood. ELISpot plates 
with predetermined antigens for use in low-technology settings 
(10), or the use of ALS (44), which can be transported relatively 
simply to reference laboratories for ELISA, have been adapted to 
these ends.
An alternative to measuring antibodies (and other proteins) 
produced in response to infection is to measure the upstream 
transcription of genes across the genome. As such, measurement 
of the abundance of RNA species in whole blood or PBMCs using 
gene expression microarrays have been used to define the tran-
scriptome in response to vaccination or infection. Theoretically, 
this approach is “hypothesis-free” regarding genes that may be 
differentially regulated in response to immunological challenge 
and relatively unbiased regarding the detection of genes (49). 
Additionally, differential gene expression precedes translation of 
proteins, and therefore may define immune response to infection 
prior to the detection of antigen-specific ASCs or antibodies in 
blood. Such gene-level data from microarray experiments can 
accurately distinguish between bacterial and viral infections at 
time of presentation to hospital (50–52) and may potentially dis-
tinguish within groups of bacterial or viral infections. Gene-level 
data may also be used to investigate immunological pathways 
activated by vaccination or colonization/infection (53). However, 
microarrays are inherently unable to define the hypervariable 
genes encoding the heavy (IGH) and light (IGL/IGK) chains of 
the BCR, and do not inform on the antigen specificity of the 
ASC response. Thus RNA microarrays are unlikely to distinguish 
between closely related infections or between serotypes of the 
same infecting pathogen.
The recent development of next-generation sequencing has 
facilitated investigation of the ASC response to immunization 
and infection at a fundamental genetic level. Sequencing of genes 
encoding the BCR has resulted in the successful production of 
monoclonal antibodies to influenza (7). Further, convergence of 
sequences encoding the BCR has been described in populations 
of B cells in the blood of adults following vaccination (54–57). The 
clinical implications and challenges of these novel techniques are 
discussed below.
ASC KiNeTiCS
Antigen-Specific ASC Responses 
to vaccination
B  cell subsets in peripheral blood are dynamic populations. 
A detailed knowledge of ASC kinetics is therefore paramount 
when sampling blood to investigate the ASC response to 
infection (Figure  2). ASC responses to natural infection may 
be dependent upon host genetic factors (58, 59), the site of 
antigen presentation (mucosal surfaces, secondary lymphoid 
organs, or systemic circulation), the type or quantity of antigen 
to which the host is exposed, and integration of other immune 
signals (derived from T  cells, pattern-recognition receptors, 
and cytokines). Onset of natural infection is typically difficult 
to define, particularly since mucosal colonization with a patho-
genic organism is likely to be a necessary precursor to many 
diseases (60–62). Practical limitations on sampling blood from 
patients with infections have limited the temporal resolution 
of studies of the ASC response to infection. These challenges 
are reduced in vaccine studies (6), where a known measure of 
antigen is administered at a specific time. The broad themes 
emerging from detailed data on ASC responses to vaccines can 
therefore be used as a point of comparison with data from the 
ASC response to infection.
The timing of the ASC response to vaccination is consistent 
between most individuals. Vaccination of adult volunteers with 
polysaccharide–protein conjugate intramuscular (IM) vaccines 
induced peak antigen-specific ASC responses at 10 days following 
vaccination of non-primed individuals. In primed individuals, 
the peak ASC responses occurred earlier, at a median of 7 days 
following vaccination (6). These adult volunteers had a median 
frequency of antigen-specific ASCs of ~50% of all ASCs in 
peripheral blood at peak time points (13, 63–65). Similarly, vac-
cination with protein IM vaccines induced peak antigen-specific 
ASC responses at 6–7 days following vaccination in primed adult 
volunteers. However, the magnitude of IgG antigen-specific 
responses varied considerably between immunoglobulin sub-
classes, and between antigens and were highest against tetanus 
toxoid (66, 67), followed by pertactin (pertussis antigen) (66) 
and hemagglutinin (influenza antigen) and lowest for diphthe-
ria toxoid (63) and hepatitis B surface protein (56). Moreover, 
responses varied between individuals in most studies by an order 
of magnitude.
The timing and magnitude of the ASC response to mucosal 
vaccines are similar to that induced by IM vaccines and appear 
conserved between bacterial and viral antigens. Antigen-specific 
ASC responses to killed oral cholera vaccine (OCV, trade name 
Dukoral) were measurable in peripheral blood at days 6–7 but not 
at day 3 or day 28 following vaccination of adults in Bangladesh 
(21). Similarly, antigen-specific ASC responses to live attenu-
ated influenza vaccine were measurable in blood between day 
7 and day 12 following intranasal administration to adults (68). 
Interestingly, both of these mucosal vaccines induced an antigen-
specific IgG ASC response that was 2–3 times higher than the 
corresponding IgA ASC response, suggesting a systemic immune 
response to these localized mucosal vaccine challenges.
FiguRe 2 | Schematic of antibody-secreting cell responses to infection as measured in peripheral blood (with supporting data and variability 
discussed in the text).
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Antigen-Specific B Cell Responses  
to Bacterial Antigens
ASC Responses to Infection in Comparison  
to Vaccination
The timing and magnitude of ASC responses may differ between 
vaccination (particularly with non-live vaccines) and infection. 
The details of studies of ASC responses to infection with bacte-
ria, viruses, and malaria are described in Tables 1  and 2. Two 
studies have directly compared the ASC response to vaccination 
and infection: enterotoxigenic Escherichia coli (ETEC) vaccine 
and challenge infection and OCV and natural infection with 
Vibrio cholerae.
Antigen-specific ASC responses to the oral attenuated ETEC 
vaccine in 20 healthy adult volunteers were compared to antigen-
specific ASC responses to challenge with oral non-attenuated 
ETEC in a further 20 healthy adult volunteers in the USA (16). 
ELISpot to ETEC vaccine or non-attenuated ETEC antigens was 
used to assay ASC responses at days 7 and 10. This study also 
compared the utility of assay of ALS to predict ASC responses. 
Volunteers who received the ETEC vaccine showed an IgA peak 
response against anti-colonization factor A II at day 7, which was 
similar to the IgA peak response against anti-heat-labile toxin in 
volunteers with non-attenuated ETEC infection. ASC responses to 
the ETEC vaccine and non-attenuated ETEC infection remained 
elevated between day 7 and day 10. Assay of IgA ALS showed 
75–95% sensitivity versus ELISpot (with a twofold increase from 
baseline defined as a positive result) for both responders to ETEC 
vaccine and non-attenuated ETEC infection at day 7. For assay of 
IgA ALS, sensitivity was reduced at day 10 in comparison to day 7.
Antigen-specific ASC responses to OCV (Dukoral) in eight 
adults were compared to antigen-specific ASC responses in nine 
adults with culture-confirmed V. cholerae O1 diarrheal disease 
(21). Median peak anti-cholera toxin (CtxB)-specific IgG ASC 
responses were detectable in both groups at day 7 following 
vaccination or onset of illness. Vaccinees tended to have lower 
median anti-CtxB-specific IgG ASCs than patients. Median peak 
anti-LPS-specific IgG ASC responses were also lower in vaccinees 
than patients. An IgG ASC response was predominant to CtxB, 
and an IgA ASC response was predominant to LPS in both vac-
cinees and patients. Flow cytometry demonstrated that ~50% of 
antigen-specific ASCs of any isotype expressed markers for gut 
homing plasmablasts. These cholera-specific plasmablasts may 
thus form the basis for gut-specific immunity following cholera 
infection.
In general, antigen-specific ASC responses appeared lower in 
adults following vaccination versus adults with challenge/natural 
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infection, at least for ETEC and cholera. This might be expected 
if infection induces coactivation of pattern-recognition receptors 
or produces a pro-ASC cytokine milieu in comparison to vac-
cination. One might hypothesize that the antigen-specific ASC 
response to infection might be over a broader timescale than that 
in response to vaccination. However, these comparative studies 
had too few time points to be able to detect this.
Gastrointestinal Infections
Other work, primarily from the International Center for Diarrheal 
Disease Research in Bangladesh, has used ELISpot and assay 
of ALS to further define the antigen-specific ASC response in 
cohorts of patients with ETEC, cholera, typhoid, and tuberculosis 
infections.
The antigen-specific ASC response was assessed in 46 adult 
patients with ETEC infection and 10 adults and 10 child healthy 
controls in Bangladesh (17). An IgA ASC response against 
colonization factor CS6 could be detected as early as 2 days fol-
lowing onset of diarrhea and then increased 30-fold by day 7. 
Healthy controls had no detectable antigen-specific IgA ASCs. In 
comparison, CS6-specific IgG ASCs were also detectable at day 
2, increased sixfold at day 7, and were undetectable in healthy 
controls. All patients with ETEC infection showed IgA ASC 
responses, but only 75% of patients showed IgG ASC responses. 
Compared to ELISpot, assay of ALS to both Ig isotypes showed 
that IgA ALS had a sensitivity of 89% for detection of antigen-
specific IgA ASC, and IgG ALS had a sensitivity of 100% for 
antigen-specific IgG ASC responses.
The IgA ASC response to cholera infection was assessed in 
30 adult patients with cholera infection and 10 healthy adult 
controls (19). The antigens CtxB, mannose-sensitive hemagglu-
tinin, and lipopolysaccharide (LPS) were used in ELISpot and 
assay of ALS. Patients showed large and significant increases 
in mean IgA ASC responses against all three antigens between 
day 2 and day 7 following onset of infection and were undetect-
able in healthy controls. ALS responses correlated well with 
antigen-specific ASC responses for all Ig isotypes. Similar large 
increases in concentrations of antigen-specific IgA ALS were 
shown for patients between day 2 and day 7 following onset of 
symptoms, and undetectable in healthy controls. Both ELISpot 
for antigen-specific IgA ASCs and IgA ALS were compared to a 
gold standard of a fourfold rise in anti-vibriocidal antibodies at 
day 7 or day 21. Antigen-specific IgA ASCs showed a maximum 
sensitivity of 94% (anti-LPS), and IgA ALS showed a maximum 
sensitivity of 94% (anti-CtxB ALS). ASCs were undetectable by 
both ELISpot and assay of ALS in healthy controls chosen from 
this cholera-endemic region, demonstrating 100% specificity in 
this setting.
Recent work has showed that children as young as 3 years of 
age produce antigen-specific IgA ASC, IgA memory B cell, and 
plasma IgA and IgG vibriocidal antibodies comparable to adults 
following cholera infection (20). The OCV Dukoral also provides 
protection from cholera infection in children between 1 and 
4  years of age (69). Infants and young children are dispropor-
tionately affected by diarrheal disease and pneumonia (discussed 
below). Both of these are primarily mucosal infections, of which 
large proportions are vaccine preventable. Further studies of the 
antigen-specific IgA and IgG ASC response in this age group are 
therefore needed.
Enteric Fever (Typhoid and Paratyphoid Infection)
Infection with Salmonella enterica serovar Typhi or Paratyphi 
occurs via the faeco-oral route. Unlike cholera, invasion beyond 
the intestinal mucosa may cause a systemic illness referred to 
as enteric fever. The antigen-specific ASC response to typhoid/
paratyphoid is of considerable interest for the development of 
diagnostic tests with increased sensitivity in comparison to cul-
ture of blood (22, 23). Typhoid-specific ASC responses may also 
inform the development of new typhoid vaccines (70).
Antigen-specific ASC responses were assessed in 112 adult 
patients in Bangladesh with suspected enteric fever and 3–7 days 
of fever at presentation to hospital. ALS assay was done at pres-
entation, day 5 and day 20, against the typhoid antigens LPS, 
whole-cell preparation, and membrane preparation (MP) (22). 
Patients were classified into comparator standards for their a pri-
ori likelihood of true typhoid infection upon the basis of blood 
culture results, serum Widal titers, and clinical features, with 
the addition of a healthy control group. A positive (≥2 standard 
deviations above the mean of healthy controls) anti-MP IgA ALS 
was detected in all patients with blood culture-positive typhoid 
infection. Mean IgA (and IgG) ALS responses at day 5 increased 
across comparator standards of blood culture-negative patients 
as the likelihood of true typhoid infection increased. Mean ALS 
responses had returned to near baseline by day 20.
A further cohort of 243 patients in Bangladesh from 1 to 
59 years of age with suspected enteric fever and 3–7 days of fever 
were assessed for ASC responses with similar ALS assay methods 
and time points (23). Similarly, patients were classified into 
comparator standards for their a priori likelihood of true typhoid 
infection, with the addition of age-matched healthy controls 
(74 people). As previously, all patients with blood culture-
positive typhoid (or paratyphoid) had positive anti-MP IgA ALS 
responses. Healthy controls all had negative ALS responses. The 
proportion of patients with positive ALS responses increased as 
the likelihood of true enteric fever increased across comparator 
standards. Of the 38 patients with positive anti-MP IgA ALS 
response, 32 (84%) had converted to a negative response by 
day 21 following enrollment (days 24–28 of illness). Five of the 
remaining six patients continued to be bacteremic for typhoid.
Taken together, the data from these cohorts suggest that the 
assay of anti-MP IgA ALS responses is a sensitive test for the diag-
nosis of enteric fever. In the absence of a single gold standard, the 
increasing proportion of positive ALS responses as the likelihood 
of enteric fever increased in comparator standards suggests that 
assay of ALS may also be specific for enteric fever.
Tuberculosis
Tuberculosis is typically a chronic intracellular infection due 
to Mycobacterium tuberculosis. Protective immune responses 
against tuberculosis are generally thought to be mainly T  cell-
mediated (71). A B cell response with anti-tuberculin IgG may 
prevent reactivation following containment within tuberculous 
granulomas (72–74), suggesting that both ASCs and other B cell 
functions are also required for protective immunity. Despite 
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its global importance, vaccination against tuberculosis using 
Bacille Calmette-Guérin (BCG) has poor efficacy against pul-
monary tuberculosis (the most common clinical manifestation). 
Tuberculosis remains difficult to diagnose, particularly in those 
living with HIV infection, the malnourished, and young children. 
The use of the antigen-specific ASC response to tuberculosis 
to assess novel vaccines and for diagnosis of disease is thus of 
considerable interest.
Forty-nine adult patients with sputum smear-positive active 
pulmonary tuberculosis in Bangladesh were assessed by assay of 
IgG ALS to BCG antigens (24). Patients with active tuberculosis 
had mean BCG-specific IgG responses that were almost an order 
of magnitude higher than the comparator standards of patients 
with other lung diseases (35 patients, with bronchiectasis, lung 
cancer, lung abscess, and aspergillosis) and healthy controls 
(35 BCG vaccinated adults). Optimization of the ELISA threshold 
value for positive ALS responses gave a sensitivity of 92% and 
specificity of 80%. These findings were validated in a further 
cohort of 212 adult patients with suspicion of pulmonary tuber-
culosis and classes of patients with other lung infections and 
healthy controls as comparator standards (26). Here, numerous 
M. tuberculosis antigens were assessed for the detection of anti-
tuberculosis IgG ALS in ELISAs. Using a threshold value similar 
to that of the previous study, assay of BCG-specific IgG ALS gave 
a sensitivity of 90% and specificity of 88% for the diagnosis of 
active tuberculosis.
Assay of ALS has also been studied for the diagnosis of active 
pulmonary tuberculosis in children in Bangladesh (25). In this 
study, children with chronic febrile illnesses aged 11 months to 
15 years of age were classified as tuberculosis patients (58 patients) 
or non-tuberculosis patients (16 patients, in whom tubercu-
losis was initially considered as a differential diagnosis, but 
ultimately diagnosed with Hodgkin’s lymphoma, intestinal 
carcinoma, non-specific lymphadenitis, pneumonia, and pneu-
monitis). Additionally, 58 age-matched healthy control children 
were enrolled. BCG was used as the antigen for the detection of 
anti-tuberculosis ALS. Using an ELISA threshold value similar to 
that of adult studies, the sensitivity of assay of IgG ALS to BCG 
antigens at baseline was 91%. In comparison, standard clinical 
scoring charts over 6  months of follow-up had a sensitivity of 
68%. All non-tuberculosis patients and healthy control children 
had negative ALS responses, suggesting a very high specificity 
of the ALS assay. Anti-BCG IgG ALS titers had reduced signifi-
cantly by days 60 and 180 in patients with (now treated) tubercu-
losis, with the median response less than the positive cutoff value.
A more recent study (28), again from Bangladesh, assessed the 
use of assay of ALS to BCG antigens for the diagnosis tuberculosis 
in 224 children admitted to hospital with radiological features 
of pneumonia and acute severe malnutrition. In this group of 
patients, using a similar ELISA threshold, sensitivity of assay 
of ALS was 67% and specificity 45% for the diagnosis of tuber-
culosis. Time points for blood sampling were not reported. It is 
unclear whether the relatively unselected nature of this cohort, 
the timing of sampling relative to treatment, or a reduction in 
immunity secondary to chronic malnutrition, reduced sensitivity 
and specificity of assay of ALS in this cohort in comparison to 
previous studies.
In addition to assay of ALS, ELISpot may also be useful for the 
diagnosis of tuberculosis. ELISpot was used to enumerate IgA 
ASCs and memory B cells from the blood of patients with active 
tuberculosis, adults with latent tuberculosis, and healthy control 
adults in Uganda (45). Four tuberculosis antigens (ESAT-6, CFP-
10, Ag85A, and Ag85b) were used. The most sensitive antigen 
was ESAT-6. ESAT 6-specific IgG ASCs were twice as high in 
adults with active tuberculosis compared with latent tuber-
culosis cases and were undetectable in healthy control adults. 
Ex vivo stimulation of PBMCs showed memory B cells to be more 
frequent in the blood of individuals with latent tuberculosis than 
in patients with active tuberculosis, suggesting a role of memory 
B  cells in controlling tuberculosis disease progression. Of 35 
healthy control adults, one had an unusual ASC to memory 
B cell ratio typical of active tuberculosis. Whether this response 
correlates with a high risk of developing tuberculosis disease is 
unknown at present.
A comparison of the utility of assay of ALS and ELISpot for the 
diagnosis of tuberculosis was made in adult patients with sputum 
smear-negative (but consequently sputum culture positive) 
tuberculosis, adults with latent tuberculosis and healthy control 
adults in Ethiopia (27). Assay of ALS to BCG antigens showed 
86% sensitivity and 80% specificity in distinguishing patients with 
active pulmonary tuberculosis from adults with latent tuberculo-
sis. Assay of ALS distinguished patients with active tuberculosis 
from healthy control adults with 86% sensitivity and 94% speci-
ficity. Assay of ALS was considerably more sensitive and specific 
than the tuberculin skin test and interferon-gamma release assay. 
Flow cytometry of PBMCs showed that patients with active 
tuberculosis had higher BCG-specific IgG-secreting plasmablasts 
than adults with latent tuberculosis or healthy control adults 
(6 versus 2% of total IgG-secreting plasmablasts).
The data from studies of tuberculosis suggest that the ASC 
response is readily detectable in patients at presentation to hospital. 
Assay of BCG-specific IgG ALS appears to have a high sensitivity 
and specificity in all cohorts assessed, except in a diverse group 
of malnourished children presenting with pneumonia. ELISpot 
and flow cytometry have shown that ASCs are detectable directly 
from blood. The chronic nature of tuberculosis may induce a 
relatively stable frequency of ASCs in the circulation. This may 
facilitate the detection of the tuberculosis-specific ASC response 
at different time points in patients with tuberculosis disease.
Pneumococcus and Other Bacterial Respiratory 
Tract Infections
Colonization with Streptococcus pneumoniae, usually in the 
nasopharynx, is common in children and a prerequisite for pneu-
mococcal disease, but most children colonized do not develop 
disease (60). Protective immune responses against pneumococci 
thus involve both prevention of infection (through clearance of 
nasopharyngeal colonization) and response to infection (should 
the mucosal surfaces be overwhelmed).
Infants and young children are likely to become colonized with 
pneumococci on first exposure to a serotype. Salivary IgA against 
pneumococcal pili proteins is secreted by ASCs in adenoids iso-
lated from healthy children (75). Low antigen-specific salivary IgA 
from adenoids and serum IgG is associated with pneumococcal 
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colonization, suggesting a protective role for mucosal antibody 
derived from local ASCs (76). Adults produce a significant 
increase in anti-capsular pneumococcal IgG to pneumococcal 
serotypes in response to pneumococcal colonization (77). The 
extent to which these responses to colonization are detectable 
as changes in populations of pneumococcus-specific ASCs in 
peripheral blood in adults or children is unknown.
Pneumococcal pneumonia represents failure to contain pneu-
mococci to the mucosal surface leading to widespread mucosal 
(alveolar) disease and in some cases bacteremia. A cohort of 
16 adult patients in Finland with bacteremic pneumococcal 
pneumonia all had detectable pneumococcal-specific IgG ASCs 
in peripheral blood on day 7 following detection of bacteremia 
(30). For each patient with pneumonia, the ELISpot antigen was 
the killed invasive pneumococcal isolate detected from the blood 
of the patient. In all patients, pneumococcal-specific IgG ASCs 
could be detected. In one of these patients with disease caused by 
serotype 14, there was also an ELISpot response against a mixture 
of purified capsular polysaccharides (3, 4, 5, 6B, 7F, 8, 14, 19F, 
and 23F). IgM and IgA ASCs were detected at lower frequencies. 
In healthy controls (14 adults), the ELISpot antigens were either 
the same mix of capsular polysaccharide antigens (n = 8) and/
or killed pneumococcal isolates (n =  14). None of the healthy 
controls showed IgG responses against any of the pneumococcal 
antigens. Total ASCs (i.e. not only pneumococcal-specific) were 
10 times higher in cases than in controls, suggesting a significant 
polyclonal ASC response.
Pneumococcal-specific ASCs derived from patients with 
bacteremic pneumococcal pneumonia (n =  16, from the study 
described above) express a unique set of homing receptors in 
comparison to pneumococcal-specific ASCs following pneumo-
coccal vaccination (n =  14 with pneumococcal polysaccharide 
vaccination and n = 11 with pneumococcal conjugate vaccination) 
(78). The authors suggest that pneumococcal-specific ASCs may 
therefore be derived from, and home to, the lung mucosa. Work 
by the same group has recently characterized the antigen-specific 
ASC response to tonsillitis and sinusitis in 24 adults caused by 
H. influenzae, S. pneumoniae, S. pyogenes, or other β-hemolytic 
streptococci (31). Peripheral blood samples were taken 7–14 days 
following onset of symptoms. These patients all showed detect-
able IgG ASC responses specific to the causative pathogen, with 
slightly higher ASC frequencies in sinusitis than tonsillitis.
Taken as a whole, pneumococcal disease induces antigen-
specific IgG ASC responses that are detectable in the peripheral 
blood of adults during illness. These ASC responses are present 
with or without detectable bacteremia. H. influenzae and non-
pneumococcal streptococcal respiratory mucosal infections 
induce a similar immune response.
Urinary Tract Infection (UTI)
Like bacterial pneumonia, UTI is usually a bacterial mucosal 
infection that may rarely invade to cause bacteremia. However, 
with appropriate sampling techniques, culture of urine is sensitive 
and specific for disease etiology in contrast to culture of blood or 
nasopharyngeal specimens in bacterial pneumonia.
A study of the antigen-specific ASC response to UTI in adults 
caused by E. coli and other bacterial pathogens found that 10/14 
(71%) patients with lower UTI and 17/17 (100%) patients with 
pyelonephritis had responses to a preparation of the cultured and 
killed E. coli isolate detectable by ELISpot at 7–8 days following 
onset of symptoms (32). In pyelonephritis, the mean antigen-
specific ASC frequency was sevenfold higher for IgA than IgG. 
Subsequent studies in adults have confirmed that IgA ASCs 
predominate in UTI (rather than IgG as in pneumococcal pneu-
monia), and that ASCs specific for the virulence factor P fimbria 
are more frequent in E. coli pyelonephritis than uncomplicated 
lower UTI (33). This has biological plausibility, since P fimbri-
ated E. coli has increased uroepithelial binding and are associated 
with increased virulence in UTI (79). Following activation in 
the urinary tract, antigen-specific ASCs express a unique set of 
homing receptors that may induce migration to regional lymph 
nodes (34).
A further study of the antigen-specific ASC response to E. coli 
pyelonephritis in children found a number of differences between 
the adult and child immune response (80). Here, 33/37 (89%) 
children aged 1 month to 16 years had responses detectable by 
ELISpot at either admission or 7  days following admission to 
hospital. Among all ages, mean antigen-specific ASC frequencies 
were comparable for IgA and IgM but lower for IgG. Antigen-
specific ASC frequency was positively correlated with increasing 
age, and all four non-responders were infants less than 1  year 
of age. In contrast to adults, among antigen-specific ASCs, IgM 
ASCs predominated in children less than 2  years of age, while 
IgA ASCs predominated in children more than 2  years of age. 
This suggests that either younger children have a reduced ability 
to class-switch to IgA ASCs in response to UTI or that a systemic 
IgM ASC response to UTI is more important in younger children 
than in older children. Alternatively, older children may have 
previously been colonized in the urinary tract with E. coli and 
have a regional memory B cell population primed to secrete IgA. 
The nuanced differences between younger children and older 
children and adults will have significant implications for the 
detection of the ASC response to infection (see “Variation in the 
B cell response between individuals” section).
Antigen-Specific B Cell Responses  
to viral Antigens
Influenza
Infection with influenza A and B viruses cause moderate upper 
respiratory tract or gastrointestinal symptoms in most adults but 
can cause life-threatening pneumonia in individuals of all ages, 
but particularly at the extremes of age and pregnant women 
(81). ItsRNA genome evolves rapidly from year to year through 
a process of antigenic drift, with occasional reassortment of 
hemagglutinin (H) and neuraminidase (N) antigens, leading to 
pandemics of novel influenza viruses (most recently the H1N1 
strain emerging in 2009) (82).
Human challenge studies have provided data on the immune 
response to respiratory infection with influenza virus (35, 83, 84). 
In most adults, challenge with influenza virus leads to rapid 
viral replication over 2–3 days during which the host is highly 
infectious. The majority of adults develop symptomatic disease 
by 2  days following challenge, with symptoms peaking at day 
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4 following exposure. Viral replication, as measured by viral 
shedding, is rare beyond 5  days following challenge (approxi-
mately 3  days following onset of symptoms) as a result of the 
induction of innate and adaptive immune responses.
In a nasal influenza challenge study in 12 adults, blood samples 
were taken at day 2, day 3, day 7, and day 28 relative to chal-
lenge (35). PBMCs were sorted for plasmablast markers before 
influenza-specific IgG ASC frequency was assessed in these 
cells using ELISpot. Influenza-specific ASCs peaked in periph-
eral blood at day 7, and were absent at day 2, day 3, and day 28 
relative to challenge. Frequency of influenza-specific IgG ASCs 
in the peripheral blood positively correlated with peak viral load, 
length of viral shedding, and symptom severity. In summary, data 
from adult influenza challenge studies of a show the emergence 
of influenza-specific ASCs between day 3 and day 7 following 
challenge, as detected by ELISpot.
Analysis of the transcriptome has been used to investigate 
gene-level changes in response to influenza challenge. In 17 
adult participants, the transcriptome was measured at 8–24 
hourly intervals for 96  h (4  days) following challenge (84). 
Strong immune responses at the interface between innate and 
adaptive immunity (for example, the toll-like receptor pathway) 
were detected at 48 h, approximately 36 h before peak symptom 
time. Notably, the upregulation of two genes was able to accu-
rately classify symptomatic from asymptomatic subjects: FGF9 
(fibroblast growth factor 9, implicated in lung epithelial repair) 
and TLN1 (Talin-1, a cytoskeletal protein). Talin-1 is essential for 
the migration of leukocytes to sites of inflammation, or to lymph 
nodes, and also stabilizes interactions between leukocytes (such 
as via the TCR) (85). However, RNA transcripts related to ASC 
activation and antibody-secretion were not detected within the 
first 96 h. This is consistent with the absence of influenza-specific 
ASCs until after at least day 3. Alternatively, hypervariable 
transcripts (such as those encoding immunoglobulins) may be 
missed by the use of microarray technology. A more sensitive 
approach for the detection of transcripts relating to hypervari-
able immunoglobulin/BCR genes is described below.
The evolving repertoire of plasmablast BCRs (and secreted 
antibodies) was studied in nine adult patients with moderate 
to severe pandemic H1N1/2009 influenza infection (86). Only 
a single time point (typically day 10 following onset of symp-
toms) was used for blood sampling. Here, flow cytometry and 
ELISpot demonstrated the presence of influenza-specific IgG 
plasmablasts, which were absent in unvaccinated healthy volun-
teers. Single cell capture, PCR amplification and sequencing of 
the heavy Ig locus (IGH) and light Ig (IGL/IGK) loci from these 
plasmablasts showed a highly somatically mutated repertoire 
of BCRs. High somatic hypermutation may be secondary to 
the derivation of plasmablasts from memory B cells through a 
recall response. However, in the context of the early pandemic of 
influenza H1N1/2009, it is likely that a proportion of the somatic 
hypermutation represents rapid molecular evolution of plasma-
blast BCRs occurring over the first 10 days of infection. This has 
significant implications for the hypothetical utility of ELISpot 
or assay of ALS for the diagnosis of the etiology of respiratory 
infections. For example, delaying sampling until several days 
following onset of symptoms might increase sensitivity (due to 
increased plasmablast numbers) and specificity (due to increas-
ing affinity of BCRs to influenza antigens).
Respiratory Syncytial Virus (RSV)
Respiratory syncytial virus is a major global pathogen causing 
upper and lower respiratory tract infection in young children 
and causes repeated symptomatic disease in otherwise healthy 
adults (87). Like influenza, RSV is an RNA virus, predisposing 
it to rapid evolution under selective pressure due to the inherent 
error rate when copying the single-stranded RNA genome. As 
with influenza virus infection, infection-derived immunity to 
RSV is of short duration (36).
In a nasal RSV challenge study in 61 adult volunteers, blood 
was sampled at days 0, 3, 7, 10, 14, and 28 post-inoculation (36). 
Using flow cytometry and ELISpot, IgA and IgG ASCs specific 
to RSV lysate were detectable at day 10 following challenge and 
undetectable before day 7 and after day 14.
In a study of 40 adults with natural RSV infection, blood was 
sampled at admission, days 10–16 following admission and again 
in convalescence (days 22–45) (37). RSV was detected in the 
nasopharynx of all patients, and patients shed RSV for a mean of 
11.9 days (range 4–30 days). RSV fusion (F)-protein antigen was 
used for ELISpot. RSV-specific IgG ASC responses were detected 
using ELISpot in 36/40 (90%) patients within 11 days following 
onset of symptoms. RSV-specific IgG ASCs were detectable by day 
2 and remained detectable until at least day 12. These ASCs were 
not detected in patients with other respiratory tract infections. 
However, 7/9 (78%) participants with a second sample at 8–16 days 
remained positive by ELISpot (>4 standard deviations above the 
mean for previously studied healthy controls). Of participants with 
a second sample at 22–45  days, 11/23 (48%) remained positive 
by ELISpot. Overall, 16/36 (44%) participants had positive 
responses beyond the last day of RSV shedding. Thus, RSV infec-
tion appears to result in antigen shedding of approximately 12 days, 
with ASC responses prolonged beyond this in many individuals.
A further adult study involving 97 participants assessed the 
frequency of antigen-specific ASCs during RSV and influenza 
infection (n = 11 each) as well as in healthy controls including 
19 adults recently vaccinated with trivalent influenza vaccine, 
tetanus toxoid vaccine, human papillomavirus vaccine (HPV) 
and hepatitis B vaccine (38). Only a single blood sample was 
taken at enrollment. All RSV-infected patients had RSV-specific 
IgG ASCs responses detectable with ELISpot at days 2–11 follow-
ing symptom onset. RSV-specific IgG ASCs were not detected in 
patients with influenza virus infection or in healthy controls with 
and without recent vaccinations. Similarly, influenza-specific 
ASCs were not detected in patients with RSV infection (except 
in a single-coinfected individual). The specificity of the ASC 
response to either RSV infection, or influenza infection suggests 
that ELISpot may be a useful test to distinguish respiratory viral 
infection from nasopharyngeal carriage. These methods may also 
be useful to investigate the immune response to RSV with the aim 
of developing an effective vaccine against this pathogen.
Dengue
Dengue virus consists of four serotypes that are transmitted by 
Aedes spp. mosquitoes in the global tropics (88). Most dengue 
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virus infections are asymptomatic or cause mild febrile illness. 
More rarely, infections can cause life-threatening disease char-
acterized by vascular endothelial damage, cardiovascular shock, 
and rapid consumption of platelets leading to coagulopathy 
(severe dengue) (89).
Severe dengue infection appears to be associated with high 
plasmablast frequencies in vivo. In a cohort of 46 adult patients 
admitted to hospital with severe dengue infection in Bangkok, 
dengue-specific IgG plasmablasts were identified by flow 
cytometry combined with ELISpot (39). These plasmablasts 
were detectable at levels above that of healthy controls from day 
4 following onset of symptoms, and peaked in frequency between 
day 6 and day 7. Median frequency of dengue-specific IgG plas-
mablasts was ~10,000 per million PBMCs, representing at least 
a 1,000-fold increase from healthy adult controls. These plasma-
blast frequencies are considerably higher than that displayed in 
other severe viral (and bacterial) infections (90, 91). A further 
study in South America has confirmed this rapid and massive 
plasmablast response and found peak plasmablast frequency to 
be associated with disease severity (40).
In a prospective study of 28 adult patients with severe den-
gue, the transcriptome showed enrichment for monocyte and 
macrophage-associated genes in comparison to controls (92). 
Enrichment for these genes was associated with higher viremia. 
Monocytes infected with dengue virus secreted proinflamma-
tory cytokines such as interleukin 1 receptor antagonist and 
induced the differentiation of B cells into plasmablasts in vitro 
after 6 days. Similar findings have been noted in other cohorts 
of children and adults (93, 94). Identification of dengue-specific 
plasmablasts (or their secretions) with ELISpot or ALS may 
represent a sensitive and specific diagnostic test for dengue 
infection from day 4 of febrile illness. This may be especially 
relevant in endemic regions where seropositivity is common in 
healthy children and adults.
The observations that (a) severe dengue occurs during rapid 
clearance of the virus, rather than during maximum viremia, 
(b) severe dengue mainly occurs in secondary infection with 
a heterotypic dengue virus serotype, and (c) plasmablasts are 
positively correlated with severity of infection, implicates the 
host immune response in the pathogenesis of severe dengue (95). 
Current evidence supports the theory of antibody-dependent 
enhancement of disease (96): invasion of dengue virions into 
monocytes (and possibly B  cells) through the FCγ receptor is 
augmented by weakly reactive B memory cell derived antibod-
ies to protein M on the viral surface (97, 98). These virions are 
rendered hypoimmunogenic (99), resulting in rapid intracellular 
replication and leading to high viremia in patients with severe 
dengue disease. Whether the phenotype of severe dengue is 
caused by the humoral immune response, or by a correlated T cell 
specific response is undetermined (100). Nonetheless, concerns 
regarding this phenomenon have hampered the development of 
a vaccine to dengue virus, further emphasizing the importance 
of pathogen-specific studies of the B cell response to infections.
Other Viral Infections: Mumps, Enterovirus
Infection with mumps virus causes parotid gland swelling and a 
moderate febrile illness in the majority of individuals, but may 
cause meningitis and encephalitis, and oophoritis, orchiditis 
in girls and boys, respectively. Complications include deafness 
and sterility (101). Mumps virus infection, or two or more live 
attenuated vaccinations (typically with measles-mumps-rubella 
vaccination, MMR), produces long-lasting immunity (102). 
However, prior vaccination complicates serological diagnosis of 
mumps infection, and assay of the ASC response to infection with 
either ELISpot or ALS may be useful in an outbreak situation.
ELISpot was used to assay mumps-specific IgG ASCs in an 
outbreak of mumps infection in seven previously vaccinated 
adults in the USA. Blood samples were taken at a single time 
point between day 7 and day 28 following onset of symptoms. 
All seven patients had detectable mumps-specific IgG ASCs 
significantly above a threshold determined from studies of 
vaccinated individuals. The single patient sampled at day 28 
had a mumps-specific IgG ASC count that was just above the 
threshold. Assay of antigen-specific ASCs may thus be a use-
ful diagnostic test in the context of prior vaccination. Further 
investigation of the BCR or antibodies derived from these ASCs 
might also illuminate the underlying reasons for vaccine failure 
in these individuals.
Enterovirus-71 (EV-71) is an RNA virus that has caused 
epidemics of herpangina and has been implicated in epidemics 
of life-threatening encephalitis and multiple organ failure in 
children in the Asia-Pacific region (103). Biennial epidemics of 
EV-71 infection occur, mainly in children aged 1–3 years. These 
epidemiological patterns, similar to pre-vaccine era measles 
epidemics (104), suggest a protective role for humoral immunity, 
with epidemics following the accrual of sufficient unprotected 
infants to allow widespread transmission.
The ASC response to acute EV-71 infection was assayed using 
ELISpot and flow cytometry on blood from 28 children with 
laboratory confirmed genotype B EV-71 infection. Blood was 
sampled once between day 2 and day 11 following symptom 
onset, and once in convalescence (>19 days following symptom 
onset) for each child. Acute blood samples showed EV-71-specific 
IgG and IgM ASCs and lower IgA ASCs. Analysis of ASCs of all 
Ig isotypes showed a strong ASC antigen-specific response at days 
1–3, which further increased ~5-fold at days 4–7, and was almost 
absent from day 8 onward. Children aged <3 years had a popula-
tion of EV-71-specific ASCs that almost entirely secreted IgM, 
while children aged >3 years showed a predominantly IgG ASC 
response. Enterovirus-specific IgG ASCs may either represent 
rapid class-switching in older children, or recall memory.
Thus, the ASC response to EV-71 infection in children has a 
similar kinetic to that described for influenza, RSV, dengue virus, 
and mumps virus infections. This suggests that there is either a 
conserved pathway to ASC activation and proliferation or several 
redundant pathways converging to the same endpoint.
Protozoa
Falciparum Malaria
Clinical malaria results from infection with one of four human 
Plasmodium spp. protozoa, with the majority of severe disease 
(anemia, acidosis and cerebral malaria) caused by Plasmodium 
falciparum infection. Naturally acquired immunity to falciparum 
malaria is generally slowly acquired (amongst survivors) over the 
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course of repeated infections in childhood in areas of endemic 
transmission (105). Following inoculation, initial invasion of the 
bloodstream by pre-hepatic sporozoites of P. falciparum does not 
induce a protective humoral response (106). Only with onset 
of clinical malaria following dissemination of merozoites is a 
protective humoral response induced.
In 38 children approximately 5  years of age with clinical 
malaria in Uganda, plasmablasts were assayed by flow cytometry 
over 28  days following presentation (107). Plasmablasts were 
already at peak levels (~6% of peripheral blood B cells) at time 
of presentation to hospital. These declined by day 7 to ~3% of 
peripheral blood B cells following treatment for malaria (107). In 
contrast, memory B cells remained at ~10% of peripheral blood 
B cells over 28 days. Atypical memory B cells (hypothesized to 
represent “exhausted” non-function B  cells (108)) increased 
from 10 to 16% of peripheral blood B cells and were positively 
associated with parasitemia on presentation. However, this study 
did not estimate the malaria-specific proportion of ASCs (or 
memory B cells), limiting its generalizability to the studies of the 
ASC response to infection.
The difficulty of defining onset of malaria infection in areas 
of endemic transmission (where a large proportion of children 
may have asymptomatic parasitemia) makes data from malaria 
challenge studies important. The majority of studies reporting 
B cell responses to malaria infection have focused on memory 
B cells and often in the context of malaria vaccination strate-
gies. However, one study quantified both the acutely activated 
malaria-specific ASC response following vaccination with 
merozoite surface protein 1 (MSP1) and the ASC response 
following malaria challenge infection. In this study, 9 healthy 
adults were enrolled and participated in a phase II trial of 
MSP1-based vaccination, with blood samples taken at days 5, 7, 
8, 9, and 15 following booster vaccination. Immediately follow-
ing day 15, 8 of 9 volunteers subsequently underwent malaria 
challenge infection with samples at baseline (day 16 following 
booster vaccination), day 7, day 11 (4 volunteers), and day 35 
following challenge. ELISpot to the MSP1 and apical membrane 
1 antigen (AMA1) was used to enumerate ASCs.
In these nine volunteers, MSP1-specific ASC responses 
post-vaccination were similar in timing (peak at day 8 and 
absent at day 15) and magnitude to those described for bacte-
rial and viral pathogens above. However, following malaria 
challenge infection MSP1-specific ASCs were undetectable at 
all time points measured. This intriguing result suggests that 
either IgG ASCs induced by malaria challenge are not cognate 
for MSP1 (unlike ASCs induced by vaccination, and despite 
this being a dominant antigen for inducing IgG memory B cell 
responses), or that malaria infection downregulates the normal 
ASC response to infection, or that the timing of the malaria-
specific ASC response differs to that of other acute infections. 
Given that only blood-stage merozoites induce a significant 
protective humoral response, and that merozoites emerged 
at approximately day 7 following challenge, one might expect 
peak malaria-specific IgG ASC responses to be identified at days 
14–17 following challenge (i.e. days 7–10 following emergence 
of merozoites).
In summary, the ASC response to malaria infection (with an 
apparent decrease in ASCs during clinical infection) is unlike 
the responses to bacterial and viral infections (where large 
increases in ASCs are typical). In studies of natural infection, 
this phenomenon may be an artifact of delayed presentation 
of children to healthcare facilities; or the comparatively long 
time from infection to clinical [approximately 10–14 days from 
inoculation (105)]. The results of malaria challenge infection 
suggest, however, that malaria may induce a maladaptive ASC 
(and possibly B memory cell) response through an unknown 
mechanism. This would be also in accord with the observed 
slow generation of immunity to clinical malaria and the loss of 
immunity to malaria in individuals who migrate out of malaria 
endemic regions.
FuTuRe STuDY AND CLiNiCAL 
APPLiCATiONS
variation in the B Cell Response between 
individuals
Despite the conservation of the ASC response to infection 
across pathogens (Table  2), a small proportion of individuals 
do not appear to produce the “normal” ASC response. Rather, 
some individuals have low or undetectable ASC responses even 
in confirmed infection. Quite why some individuals exhibit an 
abnormally low ASC response to the antigens under investigation 
is unknown. One possibility is that testing only 1–4 antigens in 
ELISpot or ALS is simply insufficient, and some individuals have 
an immune response that targets untested pathogen antigens. 
Such a possibility could be investigated using ALS against a 
protein array derived from pathogens of interest.
Alternatively, it may be that genetic variation in lymphocytes 
(109), or in the regulation of the innate and immune response 
(59), is fundamental in the ASC response to T  cell dependent 
and independent antigens (110, 111). Stochastic mechanisms 
probably determine B cell fate at the level of the individual cell 
(4, 112), which may be of importance in B cell memory (where 
the small number of memory B cells leads to a small repertoire of 
antibodies/BCRs in the quiescent state). However, given the large 
number of activated cells, this is unlikely to be of importance in 
acute infection. Immunological diagnostic tests may also be of 
limited use in the important group of patients with an impaired 
immune response (113, 114).
The relevance of abnormally low or high ASC responses to 
clinical outcome is unclear. As we have described, worsening 
clinical status in dengue virus infection is correlated with increas-
ing frequency of dengue-specific plasmablasts (40). It may be that 
plasmablast-mediated pathology is an under-appreciated aspect 
of a number of diseases. Generally, however, one would expect 
that lower ASC responses and a hypo-immune state, would 
correlate with a worse clinical outcome. An immunosuppressed 
phenotype does appear to correlate with mortality in severe sepsis 
(53), but to what extent this correlates with changes in B cell and 
T  cell compartments and to what extent this changes during 
evolving sepsis (115) are topics for future study.
(Continued)
TABLe 2 | Detection of antigen-specific ASCs via eLiSpot or ALS by disease/pathogen and time point of sampling relative to onset of symptoms.
Disease Setting Optimum method Detection of pathogen-specific ASCs by days following onset of symptoms Reference
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 21 28+
Enterotoxigenic 
E. coli  
dysentery
USA challenge 
study)
IgA ALS and ELISpot  
to LT-specific ASCs
+  + Carpenter 
et al. (16)
Urban 
Bangladesh
IgA ALS and ELISpot  
to CS6-specific ASCs
+/− +++ Qadri  
et al. (17)
Shigella spp. 
dysentery
USA 
(challenge 
study)
IgA ALS and ELISpot  
to LPS-specific ASCs 
No data regarding timing of ASC response Feller  
et al. (18)
Cholera Urban 
Bangladesh
IgA ALS and ELISpot  
to LPS-specific ASCs
+/− +++++++++ Qadri  
et al. (19)
Urban 
Bangladesh
IgG ELISpot to CtxB-
specific ASCs
− ++ − Leung  
et al. (20)
Urban 
Bangladesh
IgG ELISpot to CtxB-
specific ASCs
− ++++ − Rahman  
et al. (21)
Enteric fever Urban 
Bangladesh
IgA ALS to LPS + + + + + + ++ ++ ++ ++  + + Sheikh  
et al. (22)
Rural 
Bangladesh
IgA ALS to typhoid 
membrane preparation
+ + + + + Khanam  
et al. (23, 24)
Tuberculosis Urban 
Bangladesh
IgG ALS to BCG _______________________________________________________[+]_______________________________________________________ Raqib  
et al. (24)
Urban 
Bangladesh
IgG ALS to BCG _______________________________________________________[+]_______________________________________________________ Raqib  
et al. (25)
Urban 
Bangladesh
IgG ALS to BCG _______________________________________________________[+]_______________________________________________________ Rekha  
et al. (26)
Urban 
Ethiopia
IgG ALS to BCG _______________________________________________________[+]_______________________________________________________ Ashenafi  
et al. (27)
Urban 
Bangladesh
IgG ALS to BCG _______________________________________________________[+]_______________________________________________________ Chisti  
et al. (28)
Urban  
China
IgG ALS to SapM _______________________________________________________[+]_______________________________________________________ Jiao et al. (29)
Pneumococci 
and other 
respiratory 
bacteria
Finland IgG ASCs to pathogen ++ Palkola  
et al. (30)
Finland IgG ASCs to  
pathogen
+ ++ + ++ 
++
+ ++ 
+
++   Palkola  
et al. (31)
UTI caused by  
E. coli and  
other bacteria
Finland ASCs to pathogen +/− + (LUTI), 
+++++ (PN)
+/− Kantele  
et al. (32)
Finland ASCs to P fimbria +/− +++++ (PN) +/− Kantele  
et al. (33)
Finland ASCs to pathogen _________________+++++_______________  Kantele  
et al. (34)
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TABLe 2 | Continued
Disease Setting Optimum method Detection of pathogen-specific ASCs by days following onset of symptoms Reference
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 21 28+
Influenza UK  
(challenge 
study)a
IgG ASCs to H1N1 − ++ − Huang  
et al. (35)
USA IgG ASCs to various 
influenza antigens
___________________________________+++++___________________________________ Lee  
et al. (38)
RSV UK (challenge 
study)a
ASCs to RSV lysate − ++ +/− − Habibi  
et al. (36)
USA ASCs to RSV F  
protein
+/− ± ++ ++ ++ ++ ++ +++ 
++
++ + +/− − Lee et al. (37)
 USA ASCs to RSV F  
protein
___________________________________+++++___________________________________ Lee et al. (38)
Dengue Urban 
Thailand
IgG ASCs to dengue 
virions
++ ++++++ +++++ 
+++++
− Wrammert 
et al. (39)
Brazil IgG ASCs to DENV-3 − − + + ++ +++++++++ 
+++++++++ 
++++
+ − Garcia-Bates 
et al. (40)
Mumps USA 
(outbreak)
IgG ASCs to mumps 
virions
++ +++ + + Latner  
et al. (41)
EV-71 Taiwan IgG ASCs to EV-71 
virions
++ 
+
+++ 
++
+++ +++++++++++++++++++ +++ − Huang  
et al. (42)
Falciparum 
malariab
UK (challenge 
study)
− − − Elias et al. (43)
Notes: −describes responses measured but absent, +/− describes responses present in a few individuals with the disease, but absent in most; + describes present in the majority of individuals with disease (each + represents 
0–100 antigen-specific ASCs, either isotype specific or total as described in “Optimum method”). [+] represents measurement of ALS only (i.e., where enumeration of ASCs is not directly possible). Lines across columns (i.e., __+__) 
represent data where only a range of days is appropriate for depiction of results. ALS, antibody from lymphocyte supernatant; ASC, antibody-secreting cells; CtxB, Cholera toxin B subunit; PBMCs, peripheral blood mononuclear cells; 
LPS, lipopolysaccharide; MSHA, mannose-sensitive haemogluttinin; TB, tuberculosis; BCG, Bacille Calmette-Guérin; PPD, purified protein derivative; SapM, secretion of acid phosphatase by M. tuberculosis; ETEC, Enterotoxigenic 
Escherichia coli; CFA/II, E. coli colonizing factor; CS1, CS3, CS6, coli surface antigens; LT, heat-labile E. coli toxin; LUTI, lower urinary tract infection; PN, pyelonephritis; RSV-F, RSV fusion protein; DENV-3, dengue virus serotype 3; 
EV-71, Enterovirus-71.
aAssuming 48 h from challenge to onset of symptoms (see main text).
bNo data on timing of samples relative to symptom onset [since volunteers treated immediately following detection of parasitemia (twice daily blood samples)], hence details are for post onset of parasitemia (taken to be days 6–7 
following challenge; see main text).
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Future Clinical Applications of B Cell 
Responses to infection
The Use of ASC Kinetics for the Diagnosis of 
Infections
In this review, we have detailed the application of ELISpot and 
ALS for the study of the ASC response to infection (Table  1). 
Many of these studies have been done with the goal of develop-
ing novel diagnostic tests for a specific pathogen and in patient 
groups where there is a gold standard against which the results 
can be compared (e.g. RSV and influenza virus infection). Further 
assessment of the assay of ASC responses as diagnostic tests for 
specific pathogens needs to be done. For example, optimizing the 
antigens to use for detection of ASCs and defining the optimum 
isotype of BCR for each infection (which may also differ accord-
ing to the age of child). Most data indicate that the ASC response 
peaks at approximately 7 days following onset of illness (with the 
exception of malaria). However, future studies should consider 
using more frequent time points (e.g. daily samples for duration 
of hospital admission) in order to provide important detail on the 
timing of the ASC response.
Assay of antigen-specific ASCs for the diagnosis of the 
etiology of infection in prospectively enrolled case series is an 
important future challenge. Pneumonia provides a prototypical 
example, with multiple potential etiologies. Initial results from 
the Pneumonia Etiology Research for Child Health (PERCH) 
project suggest that microbiological diagnostic tests may be 
insensitive for bacteria (116). Studies of the impact of vaccina-
tion against specific pathogens (“vaccine probe studies”), nested 
within randomized controlled trials, provide epidemiological 
evidence for the etiology of pneumonia (117–119). Such studies 
rely on the availability of new vaccines. Alternative paradigms of 
infectious disease diagnostic testing, based on the highly specific 
ASC response to infection, or potentially the host transcriptome 
response to infection (51), are therefore attractive areas of future 
research.
The data presented here show the ASC response to differ greatly 
between individuals with similar or identical pathogen stimuli. 
Variability in the host immune response to infection, particularly 
with regard to genotype (58) and immune regulation during 
infection (59), remains an important challenge, with implica-
tions both for developing diagnostics based on the immune 
response and for understanding disease risk associated with 
this variability. Additionally, some pathogens, such as malaria, 
Epstein–Barr virus, and others, subvert the B  cell-mediated 
response, resulting in chronic infections (120). Alternatively, 
pathogens such as dengue virus appear to augment the numerical 
ASC response to infection, resulting in severe immunopathology 
(95). Other pathogens, such as Staphylococcus aureus, induce a 
potent humoral response against secretory proteins thereby 
biasing the response away from replicating bacteria (121). A 
detailed understanding therefore of both the heterogeneity of the 
immune response to a given infection and the varying strategies 
of pathogens to evade this response will inform the development 
of diagnostic testing. Such data will also be highly relevant 
to the development of vaccines and therapeutic monoclonal 
antibodies.
The BCR Repertoire to Investigate the Etiology of 
Infections
High-throughput genetic sequencing of the IGH locus and IGL 
and IGK loci that encode the BCR is now feasible allowing mil-
lions of BCR sequences to be determined simultaneously from 
a single sample (122). Technical challenges remain, including 
linking IGH and IGL/IGK sequences to represent the BCR on 
a single ASC and distinguishing genuine hypervariability in 
transcripts from read-error. Bioinformatic methods must also 
qualify the constraints on the affinity maturation of the BCR rep-
ertoire due to the baseline diversity of BCR sequences [so-called 
“original antigenic sin” (123)]. However, current data show that, 
following vaccination with either polysaccharide or protein– 
polysaccharide conjugate antigens, the detection of BCR tran-
scripts can be used to detect ASCs in PBMCs in an unbiased 
manner. Further, the plasmablast BCR repertoire undergoes con-
vergent immunological selection to a small number of vaccine 
epitopes, suggesting that antigen-specific ASCs can be detected 
(56, 57) The incremental development of a library of sequences 
that represent BCRs cognate to a variety of vaccine epitopes is 
therefore significant (54, 124).
If a similar process of convergent selection occurs during 
infection, then detection of pathogen-specific BCR sequences 
could define humoral immunity to different pathogen antigens at 
a fundamental genetic level (55, 122). Such an approach could be 
used for the etiological diagnosis of infection in a (theoretically) 
unbiased manner. A further theoretical advantage is an increased 
sensitivity early in the time course of infection due to PCR ampli-
fication of the BCR repertoire (based on primers to conserved 
regions of the BCR sequences). The successful application of this 
technique may therefore define etiology of infection in a patient 
cohort or to develop therapeutic monoclonal antibodies to exist-
ing, or emerging pathogens (125, 126).
Therapeutic Utility of B Cell Studies: Monoclonal 
Antibodies
Monoclonal antibodies may become important in the treatment 
of infectious, particularly in the context of increasing antimicro-
bial resistance and emerging infectious diseases. For example, the 
identification of a monoclonal antibody (FI6v3) that is capable 
of neutralizing all known human influenza isolates has clear 
therapeutic potential for patients with severe influenza. This was, 
however, time-consuming and derived from the screening of 
over 100,000 plasmablasts (127). Recent advances in enriching 
antigen-specific plasmablasts from vaccinees is likely to consider-
ably reduce the time and expense required to identify broadly 
neutralizing antibodies (128).
Identification of broadly neutralizing antibodies to HIV from 
individuals who are long-term non-progressors to AIDS provides 
a novel method to protect against HIV infection. The recombi-
nant gene for the broadly neutralizing antibody is engineered 
into a viral vector that is optimized for persistent transcription 
and injected intramuscularly (129). In mice models, long-lasting 
protection against HIV infection can be achieved. This technique, 
termed vectored immunoprophylaxis, provides a method to 
immunize individuals with optimized antibodies. It also does not 
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need an intact immune system and may therefore be particularly 
useful for “vaccination” against HIV in humans (130).
B  cell receptors sequencing may also become an alternative 
molecular method for identifying broadly neutralizing antibod-
ies to a range of infections. When combined with gene editing 
techniques such as CRISPR-cas9, this could provide a rapid 
method to produce monoclonal antibodies against conserved 
pathogen antigens (125, 131). Theoretically, such an approach 
may be particularly useful to develop novel therapies for pro-
longed epidemics of acute infectious diseases such as the Ebola 
virus epidemic in West Africa of 2014–2016 (126).
CONCLuSiON
A number of studies have examined the ASC response to infec-
tion across diverse bacterial and viral diseases and in malaria. 
We present a focused analysis on the timing and magnitud, and 
the clinical applications of these responses. These studies indicate 
that ELISpot and ALS may be very sensitive and highly specific 
methods for determining the etiology of infection and have some 
advantages over current methods.
The timing of the peripheral blood ASC response to infec-
tion is conserved for the bacterial pathogens (V. cholerae, E. coli, 
S. enterica var Typhi, M. tuberculosis, S. pneumonia, and other 
bacterial respiratory pathogens) and viral pathogens (influ-
enza viruses, RSV, dengue viruses, mumps virus, and EV-71) 
for which data are available. Antigen-specific ASCs generally 
express markers of acute proliferation and are detectable in 
peripheral blood by approximately day 4 following onset of 
symptoms, peak in frequency at days 6–8, and are absent from 
approximately day 11 onward. In contrast to the conserved tim-
ing of ASC detection, the magnitude of peak ASC frequency in 
peripheral blood varies widely between different bacterial and 
viral pathogens.
At present, data are too few for definitive conclusions. The 
vagaries of timing of clinical presentation of individuals and the 
infrequency of blood sampling prohibit a detailed understand-
ing of the ASC response over time (except in a few challenge 
studies involving a small number of individuals). Variability in 
the host immune response to infection, particularly with regard 
to genotype (58) and immune regulation during infection (59) 
remains an important challenge, with implications both for 
developing diagnostics based on the immune response and for 
understanding disease risk associated with this variability. More 
specifically, details of the ASC response to malaria and other 
protozoal infections are sparse.
Nonetheless, there is a great potential in the use of antigen-
specific ASCs for the etiological diagnosis of infection. Current 
efforts focus on the broadening and optimization of pathogen 
detection. This approach, however, is severely hampered by the 
frequent detection of colonizing organisms and hence difficul-
ties in defining the causative pathogen. Practical further work 
in this area should include systematic prospective sampling of 
large number of cases and appropriate controls with a similar 
clinical phenotype but with a number of potential etiologies. 
Future studies should also formally integrate data from a variety 
of current (e.g. clinical features, blood culture) and experimental 
(e.g. ELISpot, ALS and BCR sequencing) diagnostic methods to 
estimate the probable etiology of infection in cases. Such data 
may be useful to assess the burden of disease caused by various 
pathogens (e.g. in the context of planned vaccine introduction) 
and ultimately aid the development of rapid diagnostic testing 
that could inform clinicians working with patients with infectious 
disease syndromes.
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